{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:45:17Z","timestamp":1790178317304,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.neuropharm.2017.03.026","type":"journal-article","created":{"date-parts":[[2017,3,24]],"date-time":"2017-03-24T17:20:13Z","timestamp":1490376013000},"page":"223-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["A novel therapeutic with two SNAP-25 inactivating proteases shows long-lasting anti-hyperalgesic activity in a rat model of neuropathic pain"],"prefix":"10.1016","volume":"118","author":[{"given":"Jiafu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Casals-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Zurawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghui","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orla","family":"Moriarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Nealon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Om Prakash","family":"Edupuganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0861-5320","authenticated-orcid":false,"given":"Oliver","family":"Dolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.03.026_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1744-8069-1-36","article-title":"Detection of cold pain, cold allodynia and cold hyperalgesia in freely behaving rats","volume":"1","author":"Allchorne","year":"2005","journal-title":"Mol. Pain"},{"key":"10.1016\/j.neuropharm.2017.03.026_bib2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S1474-4422(16)00017-X","article-title":"Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial","volume":"15","author":"Attal","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejphar.2010.01.020","article-title":"Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection","volume":"633","author":"Bach-Rojecky","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.cell.2009.09.028","article-title":"Cellular and molecular mechanisms of pain","volume":"139","author":"Basbaum","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2017.03.026_bib5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ejpain.2005.06.009","article-title":"Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment","volume":"10","author":"Breivik","year":"2006","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.neuropharm.2017.03.026_bib6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.toxicon.2013.05.004","article-title":"The rat Digit Abduction Score (DAS) assay: a physiological model for assessing botulinum neurotoxin-induced skeletal muscle paralysis","volume":"71","author":"Broide","year":"2013","journal-title":"Toxicon"},{"key":"10.1016\/j.neuropharm.2017.03.026_bib7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0165-0270(94)90144-9","article-title":"Quantitative assessment of tactile allodynia in the rat paw","volume":"53","author":"Chaplan","year":"1994","journal-title":"J.\u00a0Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2017.03.026_bib8","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/jcmm.12562","article-title":"Botulinum neurotoxin type A modulates vesicular release of glutamate from satellite glial cells","volume":"19","author":"da Silva","year":"2015","journal-title":"J.\u00a0Cell Mol. Med."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(00)00276-1","article-title":"Spared nerve injury: an animal model of persistent peripheral neuropathic pain","volume":"87","author":"Decosterd","year":"2000","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2017.03.026_bib10","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nrneurol.2012.13","article-title":"Chronic migraine\u2013classification, characteristics and treatment","volume":"8","author":"Diener","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev.pa.20.040180.002301","article-title":"Efficient analysis of experimental observations","volume":"20","author":"Dixon","year":"1980","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib12","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/307457a0","article-title":"Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization","volume":"307","author":"Dolly","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2017.03.026_bib13","first-page":"210","article-title":"Multiprotease therapeutics for chronic pain","volume":"216","author":"Dolly","year":"2015","journal-title":"U.\u00a0S. Pat. number US9"},{"key":"10.1016\/j.neuropharm.2017.03.026_bib14","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1111\/j.1742-4658.2011.08205.x","article-title":"Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators","volume":"278","author":"Dolly","year":"2011","journal-title":"FEBS J."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib15","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1091\/mbc.e08-07-0765","article-title":"Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons","volume":"19","author":"Dong","year":"2008","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.neuropharm.2017.03.026_bib16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/bja\/aet128","article-title":"Neuroinflammation and the generation of neuropathic pain","volume":"111","author":"Ellis","year":"2013","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib17","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1177\/1073858409360822","article-title":"Glial cells and chronic pain","volume":"16","author":"Gosselin","year":"2010","journal-title":"Neuroscientist"},{"key":"10.1016\/j.neuropharm.2017.03.026_bib18","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1083\/jcb.104.6.1623","article-title":"Changes of nerve growth factor synthesis in nonneuronal cells in response to sciatic nerve transection","volume":"104","author":"Heumann","year":"1987","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib19","series-title":"Botulinum Toxin Treatment of Pain Disorders","author":"Jabbari","year":"2015"},{"key":"10.1016\/j.neuropharm.2017.03.026_bib20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.brainresrev.2008.12.011","article-title":"MAP kinase and pain","volume":"60","author":"Ji","year":"2009","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib21","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1046\/j.1471-4159.2000.0742058.x","article-title":"Nerve growth factor-induced phosphorylation of SNAP-25 in PC12 cells: a possible involvement in the regulation of SNAP-25 localization","volume":"74","author":"Kataoka","year":"2000","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib22","first-page":"895","article-title":"Central sensitization: a generator of pain hypersensitivity by central neural plasticity","volume":"10","author":"Latremoliere","year":"2009","journal-title":"J.\u00a0Pain"},{"key":"10.1016\/j.neuropharm.2017.03.026_bib23","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.neuropharm.2013.05.023","article-title":"A\u00a0back translation of pregabalin and carbamazepine against evoked and non-evoked endpoints in the rat spared nerve injury model of neuropathic pain","volume":"73","author":"Lau","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2017.03.026_bib24","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1124\/jpet.110.169342","article-title":"Excitatory cholinergic and purinergic signaling in bladder are equally susceptible to botulinum neurotoxin A consistent with co-release of transmitters from efferent fibers","volume":"334","author":"Lawrence","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib25","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1097\/j.pain.0000000000000478","article-title":"Nonparalytic botulinum molecules for the control of pain","volume":"157","author":"Mangione","year":"2016","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2017.03.026_bib26","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.neuroscience.2010.08.067","article-title":"Botulinum neurotoxin type A counteracts neuropathic pain and facilitates functional recovery after peripheral nerve injury in animal models","volume":"171","author":"Marinelli","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2017.03.026_bib27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.pneurobio.2014.06.001","article-title":"Botulinum toxin A, brain and pain","volume":"119","author":"Matak","year":"2014","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib28","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1007\/s12035-014-8665-1","article-title":"Selective cleavage of SNAREs in sensory neurons unveils protein complexes mediating peptide exocytosis triggered by different stimuli","volume":"50","author":"Meng","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib29","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1523\/JNEUROSCI.5490-08.2009","article-title":"Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential","volume":"29","author":"Meng","year":"2009","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib30","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1242\/jcs.012211","article-title":"Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential","volume":"120","author":"Meng","year":"2007","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib31","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1096\/fj.13-228973","article-title":"Molecular components required for resting and stimulated endocytosis of botulinum neurotoxins by glutamatergic and peptidergic neurons","volume":"27","author":"Meng","year":"2013","journal-title":"FASEB J."},{"issue":"21226","key":"10.1016\/j.neuropharm.2017.03.026_bib32","article-title":"TNFalpha induces co-trafficking of TRPV1\/TRPA1 in VAMP1-containing vesicles to the plasmalemma via Munc18-1\/syntaxin1\/SNAP-25 mediated fusion","volume":"6","author":"Meng","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/s-0036-1571953","article-title":"Botulinum toxin treatment of neuropathic pain","volume":"36","author":"Mittal","year":"2016","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib34","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.toxicon.2012.10.020","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders","volume":"67","author":"Naumann","year":"2013","journal-title":"Toxicon"},{"key":"10.1016\/j.neuropharm.2017.03.026_bib35","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.3390\/toxins7083127","article-title":"Botulinum toxin for neuropathic pain: a review of the literature","volume":"7","author":"Oh","year":"2015","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.neuropharm.2017.03.026_bib36","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/BF03022619","article-title":"The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain","volume":"53","author":"Park","year":"2006","journal-title":"Can. J. Anaesth."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib37","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/ana.24122","article-title":"Botulinum toxin-A treatment reduces human mechanical pain sensitivity and mechanotransduction","volume":"75","author":"Paterson","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1744-8069-3-21","article-title":"Delayed sympathetic dependence in the spared nerve injury (SNI) model of neuropathic pain","volume":"3","author":"Pertin","year":"2007","journal-title":"Mol. Pain"},{"key":"10.1016\/j.neuropharm.2017.03.026_bib39","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.bbamem.2015.08.014","article-title":"On the translocation of botulinum and tetanus neurotoxins across the membrane of acidic intracellular compartments","volume":"1858","author":"Pirazzini","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2017.03.026_bib40","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0304-3959(98)00164-X","article-title":"Effect of NGF and anti-NGF on neuropathic pain in rats following chronic constriction injury of the sciatic nerve","volume":"79","author":"Ro","year":"1999","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2017.03.026_bib41","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1523\/JNEUROSCI.20-12-04435.2000","article-title":"Extensive sprouting of sensory afferents and hyperalgesia induced by conditional expression of nerve growth factor in the adult spinal cord","volume":"20","author":"Romero","year":"2000","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib42","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pep.2005.01.016","article-title":"Protein production by auto-induction in high density shaking cultures","volume":"41","author":"Studier","year":"2005","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib43","doi-asserted-by":"crossref","first-page":"12696","DOI":"10.1002\/anie.201406359","article-title":"The molecular machinery of neurotransmitter release (Nobel lecture)","volume":"53","author":"Sudhof","year":"2014","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib44","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1017\/S1740925X08000100","article-title":"Do glial cells control pain?","volume":"3","author":"Suter","year":"2007","journal-title":"Neuron Glia Biol."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib45","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11910-012-0286-3","article-title":"Botulinum toxin for the treatment of movement disorders","volume":"12","author":"Thenganatt","year":"2012","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib46","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2174\/1570159X1201140117162802","article-title":"Pregabalin in neuropathic pain: evidences and possible mechanisms","volume":"12","author":"Verma","year":"2014","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib47","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMra1507771","article-title":"Opioid abuse in chronic pain\u2013misconceptions and mitigation strategies","volume":"374","author":"Volkow","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib48","doi-asserted-by":"crossref","first-page":"16993","DOI":"10.1074\/jbc.M710442200","article-title":"Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics","volume":"283","author":"Wang","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib49","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1074\/jbc.M110.181784","article-title":"A\u00a0dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic","volume":"286","author":"Wang","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib50","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/01.anes.0000270759.11086.e7","article-title":"Nerve conduction blockade in the sciatic nerve prevents but does not reverse the activation of p38 mitogen-activated protein kinase in spinal microglia in the rat spared nerve injury model","volume":"107","author":"Wen","year":"2007","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2017.03.026_bib51","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/nyas.12488","article-title":"Development of onabotulinumtoxinA for chronic migraine","volume":"1329","author":"Whitcup","year":"2014","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2017.03.026_bib52","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.neuroscience.2009.03.016","article-title":"Early blockade of injured primary sensory afferents reduces glial cell activation in two rat neuropathic pain models","volume":"160","author":"Xie","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2017.03.026_bib53","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/0333102416636843","article-title":"Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors' responses to stimulation of TRPV1 and TRPA1 channels: are we getting closer to solving this puzzle?","volume":"36","author":"Zhang","year":"2016","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neuropharm.2017.03.026_bib54","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ejphar.2016.09.019","article-title":"Participation of pro- and anti-nociceptive interleukins in botulinum toxin A-induced analgesia in a rat model of neuropathic pain","volume":"791","author":"Zychowska","year":"2016","journal-title":"Eur. J. Pharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817301181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817301181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T14:14:31Z","timestamp":1655561671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390817301181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":54,"alternative-id":["S0028390817301181"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.03.026","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel therapeutic with two SNAP-25 inactivating proteases shows long-lasting anti-hyperalgesic activity in a rat model of neuropathic pain","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.03.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}